Dr Reddys Laboratories Ltd 6-K, filed Oct 26, 2026
Dr Reddys Laboratories Ltd (RDY)
About this 6-K
Dr Reddys Laboratories Ltd filed this 6-K on October 26, 2026.
Deloitte Haskins & Sells LLP issued unmodified review conclusions on Dr. Reddy’s Laboratories Limited’s unaudited consolidated and standalone results for the quarter and half year ended September 30, 2026, finding no material misstatement or missing disclosures. AI summary
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
October, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit Number |
| Description of Exhibits |
|
|
|
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED | ||
|
|
|
|
Date: October 24, 2026 | By: | /s/ K Randhir Singh | |
|
| Name: | K Randhir Singh |
|
| Title: | Company Secretary |
| 3 |
Exhibit 99.1
| Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com |
October 23, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited. (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: | Limited Review Reports of the Statutory Auditors on the Unaudited Financial Results for the quarter and half year ended September 30, 2026 with Unique Document Identification Number (“UDIN”) |
With reference to our earlier intimation on unaudited financial statements for the quarter and half-year ended September 30, 2026, filed with the stock exchanges today i.e. October 23, 2026, please find enclosed the Limited Review Reports of the Statutory Auditors thereon bearing the UDIN for your records.
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR
Encl: as above
Deloitte Haskins & Sells LLP | Chartered Accountants Meenakshi Pride Rock Tower Ill [Block - M], 8th & 9th floors Survey No. 23, Gachibowli Serilingampally Municipality Ranga Reddy District Hyderabad-500032 Telangana, India |
INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS
TO THE BOARD OF DIRECTORS OF DR. REDDY'S LABORATORIES LIMITED
1. | We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Dr. Reddy's Laboratories Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/ (loss) after tax and other comprehensive income/ (loss) of its associates and joint ventures for the quarter and half year ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). |
2. | This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. |
3. | We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. |
4. | The Statement includes the results of the entities included in Appendix A. |
5. | Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. |
Regd. Office: One International Center, Tower 3, 31stfloor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India.
Deloltte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737
Page 1 of 4
Deloitte
Haskins & SellsLLP
6. | The consolidated financial results of the Group for the quarter ended June 30, 2026, and quarter and half year ended September 30, 2025, included in the Statement, were reviewed by another auditor who expressed an unmodified conclusion on those statements on July 22, 2026, and October 24, 2025, respectively. The consolidated financial results for the year ended March 31, 2026, included in the Statement were audited by another auditor who expressed an unmodified opinion on the financial statement on May 12, 2026. |
Our conclusion on the Statement is not modified in respect of this matter.
For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)
Vikas Bagaria
Partner
(Membership No. 060408)
(UDIN: 26060408CABHEY4392)
Place: Hyderabad
Date: October 23, 2026
Page 2 of 4
Deloitte
Haskins & Sells LLP
Appendix A:
Results of the entities included in Statement
Sno |
| Particulars |
| Remarks |
1 |
| Aurigene Discovery Technologies (Malaysia) Sdn. Bhd. |
| Subsidiary |
2 |
| Aurigene Oncology Limited |
| Subsidiary |
3 |
| Aurigene Pharmaceutical Services Limited |
| Subsidiary |
4 |
| beta Institute gemeinnützige GmbH |
| Subsidiary |
5 |
| betapharm Arzneimittel GmbH |
| Subsidiary |
6 |
| Cheminor Employees Welfare Trust |
| Other consolidating entity |
7 |
| Cheminor Investments Limited |
| Subsidiary |
8 |
| Clean Renewable Energy KK 2A Private Limited |
| Associate |
9 |
| Dr. Reddy's (Beijing) Pharmaceutical Co. Limited |
| Subsidiary |
10 |
| Dr. Reddy's and Nestlé Health Science Limited |
| Subsidiary |
11 |
| Dr. Reddy's Bio-Sciences Limited |
| Subsidiary |
12 |
| Dr. Reddy's Employees ESOS Trust |
| Other consolidating entity |
13 |
| Dr. Reddy's Farmaceutica Do Brasil Ltda. |
| Subsidiary |
14 |
| Dr. Reddy's Finland Oy |
| Subsidiary |
15 |
| Dr. Reddy's Formulations Limited |
| Subsidiary |
16 |
| Dr. Reddy's Laboratories (Australia) Pty. Limited |
| Subsidiary |
17 |
| Dr. Reddy's Laboratories (EU) Limited |
| Subsidiary |
18 |
| Dr. Reddy's Laboratories (Proprietary) Limited |
| Subsidiary |
19 |
| Dr. Reddy's Laboratories (Thailand) Limited |
| Subsidiary |
20 |
| Dr. Reddy's Laboratories (UK) Limited |
| Subsidiary |
21 |
| Dr. Reddy's Laboratories Canada, Inc. |
| Subsidiary |
22 |
| Dr. Reddy's Laboratories Chile SPA |
| Subsidiary |
23 |
| Dr. Reddy's Laboratories Inc. |
| Subsidiary |
24 |
| Dr. Reddy's Laboratories Jamaica Limited |
| Subsidiary |
25 |
| Dr. Reddy's Laboratories Japan KK |
| Subsidiary |
26 |
| Dr. Reddy's Laboratories Kazakhstan LLP |
| Subsidiary |
27 |
| Dr. Reddy's Laboratories LLC, Russia |
| Subsidiary |
28 |
| Dr. Reddy's Laboratories LLC, Ukraine |
| Subsidiary |
29 |
| Dr. Reddy's Laboratories Malaysia Sdn. Bhd. |
| Subsidiary |
30 |
| Dr. Reddy's Laboratories New York, LLC |
| Subsidiary |
31 |
| Dr. Reddy's Laboratories Philippines Inc. |
| Subsidiary |
32 |
| Dr. Reddy's Laboratories Romania Srl |
| Subsidiary |
33 |
| Dr. Reddy's Laboratories SA |
| Subsidiary |
34 |
| Dr. Reddy's Laboratories SAS |
| Subsidiary |
35 |
| Dr. Reddy's Laboratories Taiwan Limited |
| Subsidiary |
Page 3 of 4
Deloitte
Haskins & SellsLLP
Sno |
| Particulars |
| Remarks |
36 |
| Dr. Reddy's New Zealand Limited |
| Subsidiary |
37 |
| Dr. Reddy's Research Foundation |
| Other consolidating entity |
38 |
| Dr. Reddy's Sri |
| Subsidiary |
39 |
| Dr. Reddy's Denmark ApS |
| Subsidiary |
40 |
| Dr. Reddy's Netherlands B.V. |
| Subsidiary |
41 |
| DRES Energy Private Limited |
| Joint venture |
42 |
| DRL Impex Limited |
| Subsidiary |
43 |
| Idea2Enterprises (India) Pvt. Limited |
| Subsidiary |
44 |
| Imperial Owners and Land Possessions Private Limited |
| Subsidiary |
45 |
| Industrias Quimicas Falcon de Mexico, S.A. de CV |
| Subsidiary |
46 |
| Kunshan Rotam Reddy Pharmaceutical Co. Limited (including Kunshan Rotam Reddy Medicine Comoany Limited) |
| Joint venture |
47 |
| Lacock Holdings Limited |
| Subsidiary |
48 |
| Nimbus Health GmbH |
| Subsidiary |
49 |
| North Star OpCo Limited |
| Subsidiary |
50 |
| North Star Sweden AB |
| Subsidiary |
51 |
| Northstar Switzerland SARL |
| Subsidiary |
52 |
| O2 Renewable Energy IX Private Limited |
| Associate |
53 |
| Promius Pharma LLC |
| Subsidiary |
54 |
| Reddy Holding GmbH |
| Subsidiary |
55 |
| Reddy Netherlands B.V. |
| Subsidiary |
56 |
| Reddy Pharma Iberia SAU |
| Subsidiary |
57 |
| Reddy Pharma Italia SRL |
| Subsidiary |
58 |
| Reddy Pharma SAS |
| Subsidiary |
59 |
| Svaas Wellness Limited (ceased to be step subsidiary w.e.f April 7 2026) |
| Subsidiary |
60 |
| Dr. Reddy's Laboratories (Vietnam) Company Limited effective from May 09, 2025 |
| Subsidiary |
Page 4 of 4
Deloitte Haskins & Sells LLP | Chartered Accountants Meenakshi Pride Rock Tower III [Block - M], 8th & 9th floors Survey No. 23, Gachibowli Serilingampally Municipality Ranga Reddy District Hyderabad-500032 Telangana, India |
INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS
TO THE BOARD OF DIRECTORS OF DR. REDDY'S LABORATORIES LIMITED
1. | We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Dr. Reddy's Laboratories Limited ("the Company"), for the quarter and Half year ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). |
2. | This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. |
3. | We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. |
4. | Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. |
Regd. Office: One International Center, Tower 3, 31st floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India.
Deloitte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737
Page 1 of 2
Deloitte
Haskins & Sells LLP
5. | The standalone financial results of the Company for the quarter ended June, 30, 2026 and quarter and half year ended September 30, 2025 included in the Statement, were reviewed by another auditor who expressed an unmodified conclusion on those statements on July 22, 2026 and October 24, 2025 respectively. The Standalone financial results for the year ended March 31, 2026, included in the Statement were audited by another auditor who expressed an unmodified opinion on the financial statements on May 12, 2026. |
Our conclusion on the Statement is not modified in respect of this matter.
For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)
Vikas Bagaria
Partner
(Membership No. 060408)
(UDIN: 2606048XLHVUB4882)
Place: Hyderabad
Date: October 23, 2026
Page 2 of 2